6-Substituted-2,3,4,5-Tetrahydro-1H-Benzo[d]Azepines as 5-Ht2c Receptor Agonists
申请人:Allen John Gordon
公开号:US20080255092A1
公开(公告)日:2008-10-16
The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HT2C receptor agonists for the treatment of 5-HT2c associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: R6 D R?N—R″R* where R6 is —(CrC3)alkyl-S—(C0-C3)alkyl-R10, —(C1-C3)alkyl-NR11R12, —(CrC3)alkyl-O—R13. and other substituents are as defined in the specification.
6-substituted-2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists
申请人:Eli Lilly and Company
公开号:US07994163B2
公开(公告)日:2011-08-09
The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HT2C receptor agonists for the treatment of 5-HT2c associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: R6 D R?N—R″R* where R6 is —(CrC3)alkyl-S—(C0-C3)alkyl-R10, —(C1-C3)alkyl-NR11R12, —(CrC3)alkyl-O—R13. and other substituents are as defined in the specification.
本发明提供了式(I)的6-取代2,3,4,5-四氢-1H-苯并[d]氮杂环化合物,作为选择性5-HT2C受体激动剂,用于治疗与5-HT2c相关的疾病,包括肥胖症、强迫/强迫症、抑郁症和焦虑症:R6 D R?N—R″R*,其中R6为—(CrC3)烷基-S—(C0-C3)烷基-R10,—(C1-C3)烷基-NR11R12,—(CrC3)烷基-O—R13。其他取代基如规范中所定义。
6-SUBSTITUTED- 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS
申请人:ELI LILLY AND COMPANY
公开号:EP1924560B1
公开(公告)日:2009-08-05
US7994163B2
申请人:——
公开号:US7994163B2
公开(公告)日:2011-08-09
[EN] 6-SUBSTITUTED- 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS<br/>[FR] 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES 6-SUBSTITUEES EN TANT QU'ANTAGONISTES DU RECEPTEUR 5-HT2C
申请人:LILLY CO ELI
公开号:WO2007028082A1
公开(公告)日:2007-03-08
[EN] The present invention provides 6-substituted 2,3,4,5-tetrahydro-lH- benzo[d]azepines of Formula (I) as selective 5-HT2C receptor agonists for the treatment of 5-HT2c associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: R6 D R? N-R" R* where R6 is -(CrC3)alkyl-S-(C0-C3)alkyl-R10, -(C1-C3)alkyl-NR11R12, -(CrC3)alkyl-O- R 13. and other substituents are as defined in the specification. [FR] La présente invention concerne des 2,3,4,5-tétrahydro-1H-benzo[d]azépines 6-substituées de Formule (I) en tant qu'antagonistes sélectifs du récepteur 5-HT2C destinés au traitement de troubles liés à 5-HT2c, y compris l'obésité, les troubles obsessifs/compulsifs, la dépression, et l'anxiété : R6 D R? N-R' R*, dans laquelle R6 est -(CrC3)alkyl-S-(C0-C3)alkyl-R10, -(C1-C3)alkyl-NR11R12, -(CrC3)alkyl-O-, R13 et les autres substituants étant tels que définis dans la description.